Skip to main content
. 2014 Apr 10;9(4):e94561. doi: 10.1371/journal.pone.0094561

Figure 7. Dose-response curves for peptide-fusion protein and MAP30.

Figure 7

The figure shows the effect of increasing concentrations of the peptide-fusion protein and MAP30 peptides against DENV2. The peptide-fusion protein showed a maximum inhibitory activity against DENV2 of 18.6%±7.2 at 0.75 μM with EC50 about 0.43 μM. MAP30 showed a maximum inhibition activity against DENV2 of 68.9%±6.7 at 0.75 μM with EC50 more than 0.75 μM. Results are expressed as mean ± SD from a representative experiment performed in triplicate. Asterisk denotes statistically significant differences between peptide-fusion protein and MAP30. (Two-way ANOVA with Bonferroni post-test, p<0.001).

HHS Vulnerability Disclosure